

Buy-back of ordinary shares in BONESUPPORT HOLDING AB 9-12 June 2026 (week 24)

BONESUPPORT HOLDING AB (LEI CODE: 549300COLY053IGTLD63) ("BONESUPPORT") has during 9 June 2026 up to and including 12 June 2026 repurchased a total of 180,000 own ordinary shares (ISIN: SE0009858152) as part of the buy-back program initiated by the Board of Directors of BONESUPPORT™.

The repurchases are part of the buy-back program of maximum 373,320 ordinary shares for a total amount of maximum SEK 100 million announced by BONESUPPORT on 8 June 2026 and which runs during the period 9 June 2026 until no later than 9 July 2026. The buy-back program is carried out for the purpose of ensuring BONESUPPORT's obligations arising from the long-term share savings program LTI 2026 resolved by the Annual General Meeting on 12 May 2026. The repurchases are carried out in accordance with the Market Abuse Regulation (EU) 596/2014 ("MAR") and the European Commission Delegated Regulation (EU) 2016/1052 (the "Safe Harbour Regulation").

Ordinary shares in BONESUPPORT have been repurchased as follows:

Date	Aggregate daily volume (number of shares)	Weighted average price per day (SEK)	Total Daily Transaction Value (SEK)
9 June 2026	50,000	227.1924	11,359,620
10 June 2026	35,000	227.2857	7,955,000
11 June 2026	50,000	231.8632	11,593,161
12 June 2026	45,000	229.1722	10,312,748

All repurchases have been carried out on Nasdaq Stockholm by DNB Carnegie Investment Bank AB (publ) on behalf of BONESUPPORT. Following the above repurchases, BONESUPPORT's holding of treasury shares up to and including 12 June 2026 amounts to 180,000 ordinary shares and 905,155 Series C shares.

As of 12 June 2026, the total number of shares in BONESUPPORT, including treasury shares, is 66,764,350, of which 65,859,195 are ordinary shares and 905,155 are Series C shares. The total number of outstanding shares in BONESUPPORT, excluding treasury shares, is 65,679,195, all of which are ordinary shares.

Complete information about the transactions carried out in accordance with Article 5.3 of MAR and Article 2.3 of the Safe Harbour Regulation is attached to this press release.

Press Release
15 June 2026 14:05:00 CEST



For more information contact:

BONESUPPORT Holding AB
Torbjörn Sköld, CEO
+46 (0) 46 286 53 70

Håkan Johansson, CFO
+46 (0) 46 286 53 70
ir@bonesupport.com

Cord Communications
Charlotte Stjerngren
+46 (0) 708 76 87 87
charlotte.stjerngren@cordcom.se
www.cordcom.se

About BONESUPPORT™

BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient's own bone and have the capability of eluting drugs. BONESUPPORT's bone graft substitutes are based on the patented technology platform **CERAMENT**. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to 1,175 msek in 2025. Please visit www.bonesupport.com for more information.

BONESUPPORT and CERAMENT are **registered trademarks** of BONESUPPORT AB.

Attachments

Supplement Share Buyback Week 24 2026

Buy-back of ordinary shares in BONESUPPORT HOLDING AB 9-12 June 2026 (week 24)